Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Prezcobix launched in Canada for HIV

Sep. 18, 2014

Group in Thailand generates novel series of multivalent HIV-1 integrase inhibitors

Sep. 5, 2014

ViiV Healthcare receives E.U. marketing authorization for Triumeq

Sep. 4, 2014

FDA approves Triumeq for HIV

Aug. 26, 2014

NIH awards grant to Sedia Biosciences for rapid HIV-1 incidence assay

Aug. 19, 2014

CytoDyn reports interim data from phase IIb trial of PRO-140 in patients with HIV

Aug. 1, 2014

Theraclone forms agreement with Gilead Sciences for neutralizing HIV antibodies

Aug. 1, 2014

Gilead Sciences synthesizes novel antiretrovirals

July 31, 2014

Novel RNA-based transcriptional gene silencing strategy inhibits HIV-1 activation in vitro

July 29, 2014

Phase II results presented for TB vaccine in HIV-infected adults

July 28, 2014

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...